Cimetidine 99.0%(HPLC)
99.0%(HPLC)
Properties
| Vapour pressure | 0.0±1.2 mmHg at 25℃ |
| Water Solubility | Practically insoluble |
| Assay Purity | >99%(HPLC) |
| Refractive index | 1.632 |
| B pt. | 488℃ at 760 mmHg |
| M pt. | 141℃ |
| Density | 1.27 g/cm3 |
Safety Information
| Hazard Statement(s) | H360 |
| Precautionary Statement | P201 - P202 - P280 - P308 + P313 - P405 - P501 |
| Symbol |
|
| Signal word | Danger |
| HS Code | 2933990090 |
| Flash point | 248.9℃ |
| Storage Temp. | 2-8℃ |
| Packaging | Glass Bottle |
Description
Application
Cimetidine (INN) is a histamine H2 receptor antagonist that inhibits stomach acid production. It is largely used in the treatment of heartburn and peptic ulcers.
Purpose
For R&D use onlynot for drug household or other uses.
General Description
Cimetidine was discovered in 1971. It has been marketed by GlaxoSmithKline (which is selling the brand to Prestige Brands) under the trade name Tagamet (sometimes Tagamet HB or Tagamet HB200). Cimetidine was approved in the UK in 1976 and was approved in the US by the Food and Drug Administration for prescriptions starting January 1 1979.
Documents
| SDS |
| COA |
| Specification |
| Bulk quote order form |